<DOC>
	<DOC>NCT01021943</DOC>
	<brief_summary>The main objective of this study is to assess the effect of spironolactone on interstitial fibrosis in kidney transplant recipients receiving calcineurin inhibitors</brief_summary>
	<brief_title>Spironolactone and Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Kidney Failure Age &gt; 18 Kidney transplant recipients Patients taking angiotensin receptor blockers or inhibitors of the angiotensin reconverting enzyme Kidney transplant performed more than one month from enrollment in the study Hyperkalemia (K&gt; 5.5 meqL)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>calcineurin inhibitors</keyword>
	<keyword>fibrosis</keyword>
	<keyword>spironolactone</keyword>
	<keyword>Focus of the study is to assess if aldosterone blockade has an effect on interstitial fibrosis amongst kidney transplant recipients</keyword>
</DOC>